相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States
Richard E. Nelson et al.
CLINICAL INFECTIOUS DISEASES (2022)
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
Christopher A. Darlow et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia
Soo Tein Ngoi et al.
ANTIBIOTICS-BASEL (2021)
Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
Mariana Castanheira et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
Shuhei Matsumoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Carbapenem-Sparing Strategies for ESBL Producers: When and How
Ilias Karaiskos et al.
ANTIBIOTICS-BASEL (2020)
Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam
Hiroki Namikawa et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
In vitro activity of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea
Younghee Jung et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship
Silvia Corcione et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan
Yoshio Takesue et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: Comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015 (vol 23, pg 339, 2017)
Yoshio Takesue et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Transmission of ESBL-producing Enterobacteriaceae and their mobile genetic elements-identification of sources by whole genome sequencing: study protocol for an observational study in Switzerland
Tanja Stadler et al.
BMJ OPEN (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan
Yuko Komatsu et al.
PLOS ONE (2018)
The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world
Yohei Doi et al.
JOURNAL OF TRAVEL MEDICINE (2017)
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Belen Gutierrez-Gutierrez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Community spread of extended-spectrum β-lactamase-producing bacteria detected in social insurance hospitals throughout Japan
Mayumi Shibasaki et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2016)
Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia
Yasufumi Matsumura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum β-Lactamase Bacteremia
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2015)
Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infections
Qiwen Yang et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
In vitro activity of flomoxef and comparators against Escherichia coil, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China
Qiwen Yang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Mechanism of resistance and antibacterial susceptibility in extended-spectrum β-lactamase phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and 2010 in Japan
Takafumi Sato et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2015)
Community-Associated Extended-Spectrum β-Lactamase-Producing Escherichia coli Infection in the United States
Yohei Doi et al.
CLINICAL INFECTIOUS DISEASES (2013)
Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery
Arantxazu Isla et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
In Vitro Pharmacokinetic and Pharmacodynamic Evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae
Tomoyuki Homma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Infections with Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Changing Epidemiology and Drug Treatment Choices
Johann D. D. Pitout
DRUGS (2010)
International prospective study Klebsiella pneumoniae bacteremia:: Implications of extended-spectrum β-lactamase production in nosocomial infections
DL Paterson et al.
ANNALS OF INTERNAL MEDICINE (2004)
Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy
CI Kang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period
DS Burgess et al.
PHARMACOTHERAPY (2003)
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection:: risk factors and clinical outcome
B Du et al.
INTENSIVE CARE MEDICINE (2002)
分享论文
